SGL Investment Advisors Inc. lessened its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 21.5% in the third quarter, HoldingsChannel.com reports. The firm owned 21,416 shares of the medical research company’s stock after selling 5,874 shares during the period. Quest Diagnostics comprises 1.9% of SGL Investment Advisors Inc.’s holdings, making the stock its 18th largest position. SGL Investment Advisors Inc.’s holdings in Quest Diagnostics were worth $5,475,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Quest Diagnostics in the 2nd quarter valued at $1,965,923,000. EdgePoint Investment Group Inc. raised its stake in shares of Quest Diagnostics by 35.1% in the first quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock valued at $439,753,000 after buying an additional 582,797 shares during the period. Dimensional Fund Advisors LP raised its stake in Quest Diagnostics by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,949,535 shares of the medical research company’s stock valued at $382,085,000 after acquiring an additional 17,987 shares during the period. Bank of America Corp DE purchased a new stake in shares of Quest Diagnostics during the 2nd quarter valued at approximately $410,151,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Quest Diagnostics by 11.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 942,407 shares of the medical research company’s stock worth $199,743,000 after acquiring an additional 95,804 shares in the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
DGX has been the topic of a number of analyst reports. Truist Financial increased their price objective on Quest Diagnostics from $250.00 to $260.00 and gave the stock a “hold” rating in a report on Monday, September 21st. UBS Group restated a “neutral” rating and issued a $250.00 target price on shares of Quest Diagnostics in a research note on Monday, October 19th. Jefferies Financial Group reaffirmed a “buy” rating and set a $245.00 target price on shares of Quest Diagnostics in a report on Thursday, July 23rd. Mizuho upped their price target on Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Wall Street Zen upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Quest Diagnostics has an average rating of “Moderate Buy” and an average target price of $248.70.
Read Our Latest Report on Quest Diagnostics
Quest Diagnostics Stock Performance
NYSE DGX opened at $259.46 on Monday. Quest Diagnostics Incorporated has a 1 year low of $171.18 and a 1 year high of $262.00. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.70 and a quick ratio of 1.58. The stock has a market capitalization of $28.55 billion, a PE ratio of 25.84, a P/E/G ratio of 2.32 and a beta of 0.54. The company’s 50 day simple moving average is $241.23 and its two-hundred day simple moving average is $215.58.
Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its quarterly earnings results on Thursday, October 22nd. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.87 by $0.13. The firm had revenue of $3.10 billion during the quarter, compared to the consensus estimate of $3.05 billion. Quest Diagnostics had a net margin of 9.53% and a return on equity of 16.21%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period last year, the firm earned $2.60 EPS. Analysts predict that Quest Diagnostics Incorporated will post 11.29 earnings per share for the current fiscal year.
Quest Diagnostics Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 27th. Investors of record on Tuesday, January 12th will be given a $0.86 dividend. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date is Tuesday, January 12th. Quest Diagnostics’s dividend payout ratio (DPR) is 34.26%.
Top Quest Diagnostics Stories
Investors following DGX have been watching these stories:
- Positive Sentiment: A Yahoo Finance article says DGX could be 31% undervalued following a push for the RESULTS Act, providing a potentially supportive policy and valuation angle. Quest Diagnostics stock could be undervalued following RESULTS Act push
- Neutral Sentiment: SVP Patrick Plewman sold 11,717 shares for about $3.02 million, reducing his holdings by 44.38%. The sale was made under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive signal about his view of the company. Quest Diagnostics insider share sale
- Negative Sentiment: Zacks lowered its Q4 2026 EPS estimate to $2.66 from $2.70, partially offsetting the upward revisions for other periods.
Insider Buying and Selling
In related news, CEO J. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the completion of the sale, the chief executive officer owned 122,423 shares of the company’s stock, valued at approximately $29,714,510.56. This trade represents a 7.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Catherine Doherty sold 22,105 shares of Quest Diagnostics stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $248.02, for a total value of $5,482,482.10. Following the sale, the executive vice president directly owned 71,949 shares of the company’s stock, valued at $17,844,790.98. This represents a 23.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,702 shares of company stock valued at $16,730,269 in the last ninety days. 0.88% of the stock is owned by insiders.
Quest Diagnostics Profile
Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.
Featured Articles
- Five stocks we like better than Quest Diagnostics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
